𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tumor necrosis factor α haplotypes versus tumor necrosis factor α −308 G/A polymorphism in the prediction of infliximab treatment efficacy in rheumatoid arthritis

✍ Scribed by Bénédicte Mugnier; Jean Roudier

Publisher
John Wiley and Sons
Year
2004
Tongue
English
Weight
112 KB
Volume
50
Category
Article
ISSN
0004-3591

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Polymorphism at position −308 of the tum
Polymorphism at position −308 of the tumor necrosis factor α gene influences outcome of infliximab therapy in rheumatoid arthritis
✍ Benedicte Mugnier; Nathalie Balandraud; Albert Darque; Chantal Roudier; Jean Rou 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 62 KB

## Abstract ## Objective To test whether the G‐to‐A polymorphism at position −308 in the promoter of the tumor necrosis factor α (TNFα) gene influences response to infliximab therapy in patients with rheumatoid arthritis (RA). ## Methods We genotyped 59 RA patients by polymerase chain reaction a

Detection of tumor necrosis factor α but
Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum
✍ T. Saxne; M. A. Palladino Jr; D. Heinegãrd; N. Talal; F. A. Wollheim 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 386 KB 👁 1 views

Synovial fluids from 6 of 12 patients with rheumatoid arthritis (RA) and from 3 of 11 patients with reactive arthritis contained measurable levels of tumor necrosis factor a (TNFa). Seven of 12 sera from RA patients contained TNFa, while only 1 of those from reactive arthritis patients was positive.

Individualized monitoring of drug bioava
Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab
✍ Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C. Kapetan 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 1 views

## Abstract ## Objective Infliximab, an anti–tumor necrosis factor α (anti‐TNFα) antibody, is effective in the treatment of several immunoinflammatory diseases. However, many patients experience primary or secondary response failure, suggesting that individualization of treatment regimens may be b

Anti–tumor necrosis factor α therapy and
Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answer
✍ Deborah P. M. Symmons; Alan J. Silman 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 50 KB

The authors are the principal investigators of the British Society of Rheumatology (BSR) Biologics Register. The BSR receives financial support for the Register from the manufacturers of biologic agents currently licensed for use in the treatment of patients with inflammatory rheumatic diseases. The